The novel albumin–chitosan core–shell nanoparticles for gene delivery: preparation, optimization and cell uptake investigation
Source abstract
Abstract
Natural polymers and proteins such as chitosan (CS) and albumin (Alb) have recently attracted much attention both in drug delivery and gene delivery. The underlying rationale is their unique properties such as biodegradability, biocompatibility and controlled release. This study aimed to prepare novel albumin-chitosan-DNA (Alb-CS-DNA) core-shell nanoparticles as a plasmid delivery system and find the best conditions for their preparation. Phase separation method and ionic interaction were used for preparation of Alb nanoparticles and Alb-CS-DNA core-shell nanoparticles, respectively. The effects of three important independent variables (1) CS/Alb mass ratio, (2) the ratios of moles of the amine groups of cationic polymers to those of the phosphate groups of DNA (N/P ratio), and (3) Alb concentration, on the nanoparticle size and loading efficiency of the plasmid were investigated and optimized through Box-Behnken design of response surface methodology (RSM). The optimum conditions were found to be CS/Alb mass ratio = 3, N/P ratio = 8.24 and Alb concentration = 0.1 mg/mL. The most critical factors for the size of nanoparticles and loading efficiency were Alb concentration and N/P ratio. The optimized nanoparticles had an average size of 176 ± 3.4 nm and loading efficiency of 80 ± 3.9 %. Cytotoxicity experiments demonstrated that the prepared nanoparticles were not toxic. The high cellular uptake of nanoparticles (~85 %) was shown by flow cytometry and fluorescent microscopy.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (52)
Show source-provided references
1. Arya G, Vandana M, Acharya S, Sahoo SK (2011) Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy. Nanomedicine: Nanotechnology, Biology and Medicine 7(6):859–87010.1016/j.nano.2011.03.009 ↗
2. Azarmi S, Tao X, Chen H, Wang Z, Finlay WH, Löbenberg R, Roa WH (2006) Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int J Pharm 319(1–2):155–16110.1016/j.ijpharm.2006.03.052 ↗
3. Banerjee N, Krupanidhi SB (2010) Facile hydrothermal synthesis and observation of bubbled growth mechanism in nano-ribbons aggregated microspherical Covellite blue-phosphor. Dalton Trans 39(41):9789–979310.1039/c0dt00386g ↗
4. Bansal KK, Kakde D, Gupta U, Jain NK (2010) Development and characterization of triazine based dendrimers for delivery of antitumor agent. J Nanosci Nanotechnol 10(12):8395–840410.1166/jnn.2010.3003 ↗
5. Che H-L, Muthiah M, Ahn Y, Son S, Kim WJ, Seonwoo H, Chung JH, Cho C-S, Park I-K (2011) Biodegradable particulate delivery of vascular endothelial growth factor plasmid from polycaprolactone/polyethylenimine electrospun nanofibers for the treatment of myocardial infarction. J Nanosci Nanotechnol 11(8):7073–707710.1166/jnn.2011.4862 ↗
6. Cryan SA, Holohan A, Donohue R, Darcy R, O’Driscoll CM (2004) Cell transfection with polycationic cyclodextrin vectors. Eur J Pharm Sci 21(5):625–63310.1016/j.ejps.2004.01.001 ↗
7. De Laporte L, Cruz Rea J, Shea LD (2006) Design of modular non-viral gene therapy vectors. Biomaterials 27(7):947–95410.1016/j.biomaterials.2005.09.036 ↗
8. De Souza Costa-Junior E, Pereira MM, Mansur HS (2009) Properties and biocompatibility of chitosan films modified by blending with PVA and chemically crosslinked. J Mater Sci Mater Med 20(2):553–56110.1007/s10856-008-3627-7 ↗
9. Dong CH, Xie XQ, Wang XL, Zhan Y, Yao YJ (2009) Application of Box-Behnken design in optimisation for polysaccharides extraction from cultured mycelium of Cordyceps sinensis. Food Bioprod Process 87(2):139–14410.1016/j.fbp.2008.06.004 ↗
10. Duan Y, Zheng J, Han S, Wu Y, Wang Y, Li D, Kong D, Yu Y (2008) A tumor targeted gene vector modified with G250 monoclonal antibody for gene therapy. J Control Release 127(2):173–17910.1016/j.jconrel.2008.01.016 ↗
11. El-Aneed A (2004) An overview of current delivery systems in cancer gene therapy. J Control Release 94(1):1–1410.1016/j.jconrel.2003.09.013 ↗
12. Elzoghby AO, Samy WM, Elgindy NA (2012) Albumin-based nanoparticles as potential controlled release drug delivery systems. J Controlled Release 157(2):168–18210.1016/j.jconrel.2011.07.031 ↗
13. Fischer D, Li Y, Ahlemeyer B, Krieglstein J, Kissel T (2003) In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 24(7):1121–113110.1016/S0142-9612(02)00445-3 ↗
14. Gazori T, Khoshayand MR, Azizi E, Yazdizade P, Nomani A, Haririan I (2009) Evaluation of Alginate/Chitosan nanoparticles as antisense delivery vector: formulation, optimization and in vitro characterization. Carbohydr Polym 77(3):599–60610.1016/j.carbpol.2009.02.019 ↗
15. Ge S, Kojio K, Takahara A, Kajiyama T (1998) Bovine serum albumin adsorption onto immobilized organotrichlorosilane surface: influence of the phase separation on protein adsorption patterns. J Biomater Sci Polym Ed 9(2):131–15010.1163/156856298X00479 ↗
16. Howard KA, Rahbek UL, Liu X, Damgaard CK, Glud SZ, Andersen MO, Hovgaard MB, Schmitz A, Nyengaard JR, Besenbacher F, Kjems J (2006) RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther 14(4):476–48410.1016/j.ymthe.2006.04.010 ↗
17. Huang P, Kong Y, Li Z, Gao F, Cui D (2010) Copper selenide nanosnakes: bovine serum albumin-assisted room temperature controllable synthesis and characterization. Nanoscale Res Lett 5(6):949–95610.1007/s11671-010-9587-0 ↗
18. Irache JM, Merodio M, Arnedo A, Camapanero MA, Mirshahi M, Espuelas S (2005) Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugs. Mini Rev Med Chem 5(3):293–30510.2174/1389557053175335 ↗
19. Janes KA, Fresneau MP, Marazuela A, Fabra A, Alonso MJ (2001) Chitosan nanoparticles as delivery systems for doxorubicin. J Control Release 73(2–3):255–26710.1016/S0168-3659(01)00294-2 ↗
20. Kim TH, Jin H, Kim HW, Cho MH, Cho CS (2006) Mannosylated chitosan nanoparticle-based cytokine gene therapy suppressed cancer growth in BALB/c mice bearing CT-26 carcinoma cells. Mol Cancer Ther 5(7):1723–173210.1158/1535-7163.MCT-05-0540 ↗
21. Kim J, Lee C-M, Jeong H-J, Lee K-Y (2011a) In vivo tumor accumulation of nanoparticles formed by ionic interaction of glycol chitosan and fatty acid ethyl ester. J Nanosci Nanotechnol 11(2):1160–116610.1166/jnn.2011.3569 ↗
22. Kim T-H, Yu GS, Choi H, Shim YJ, Lee M, Choi JS (2011b) Preparation of dexamethasone-based cationic liposome and its application to gene delivery in vitro. J Nanosci Nanotechnol 11(2):1799–180210.1166/jnn.2011.3407 ↗
23. Kommareddy S, Amiji M (2005) Preparation and evaluation of thiol-modified gelatin nanoparticles for intracellular DNA delivery in response to glutathione. Bioconjug Chem 16(6):1423–1432. doi: 10.1021/bc050146t10.1021/bc050146t ↗
24. Kratz F (2008) Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 132(3):171–18310.1016/j.jconrel.2008.05.010 ↗
25. Kratz F, Fichtner I, Beyer U, Schumacher P, Roth T, Fiebig HH, Unger C (1997) Antitumour activity of acid labile transferrin and albumin doxorubicin conjugates in in vitro and in vivo human tumour xenograft models. Eur J Cancer 33(1008):17510.1016/S0959-8049(97)85428-7 ↗
26. Langer K, Balthasar S, Vogel V, Dinauer N, von Briesen H, Schubert D (2003) Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm 257(1–2):169–18010.1016/S0378-5173(03)00134-0 ↗
27. Lavertu M, Méthot S, Tran-Khanh N, Buschmann MD (2006) High efficiency gene transfer using chitosan/DNA nanoparticles with specific combinations of molecular weight and degree of deacetylation. Biomaterials 27(27):4815–482410.1016/j.biomaterials.2006.04.029 ↗
28. Lee D, Lockey R, Mohapatra S (2006) Folate receptor-mediated cancer cell specific gene delivery using folic acid-conjugated oligochitosans. J Nanosci Nanotechnol 6(9–10):2860–286610.1166/jnn.2006.465 ↗
29. Lee K-M, Lee Y-B, Oh I-J (2011) Evaluation of PEG-transferrin-PEI nanocomplex as a gene delivery agent. J Nanosci Nanotechnol 11(8):7078–708110.1166/jnn.2011.4863 ↗
30. Mansouri S, Cuie Y, Winnik F, Shi Q, Lavigne P, Benderdour M, Beaumont E, Fernandes JC (2006) Characterization of folate-chitosan-DNA nanoparticles for gene therapy. Biomaterials 27(9):2060–206510.1016/j.biomaterials.2005.09.020 ↗
31. Mao H-Q, Roy K, Troung-Le VL, Janes KA, Lin KY, Wang Y, August JT, Leong KW (2001) Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Controlled Release 70(3):399–42110.1016/S0168-3659(00)00361-8 ↗
32. Mao S, Sun W, Kissel T (2010) Chitosan-based formulations for delivery of DNA and siRNA. Adv Drug Deliv Rev 62(1):12–2710.1016/j.addr.2009.08.004 ↗
33. Mayer G, Vogel V, Weyermann J, Lochmann D, van den Broek JA, Tziatzios C, Haase W, Wouters D, Schubert US, Zimmer A, Kreuter J, Schubert D (2005) Oligonucleotide-protamine-albumin nanoparticles: protamine sulfate causes drastic size reduction. J Control Release 106(1–2):181–18710.1016/j.jconrel.2005.04.019 ↗
34. Muthukumar M, Mohan D, Rajendran M (2003) Optimization of mix proportions of mineral aggregates using Box Behnken design of experiments. Cement Concr Compos 25(7):751–75810.1016/S0958-9465(02)00116-6 ↗
35. Nagpal K, Singh SK, Mishra DN (2010) Chitosan nanoparticles: a promising system in novel drug delivery. Chem Pharm Bull (Tokyo) 58(11):1423–143010.1248/cpb.58.1423 ↗
36. Nasti A, Zaki NM, de Leonardis P, Ungphaiboon S, Sansongsak P, Rimoli MG, Tirelli N (2009) Chitosan/TPP and chitosan/TPP-hyaluronic acid nanoparticles: systematic optimisation of the preparative process and preliminary biological evaluation. Pharm Res 26(8):1918–193010.1007/s11095-009-9908-0 ↗
37. Park TG, Jeong JH, Kim SW (2006) Current status of polymeric gene delivery systems. Adv Drug Deliv Rev 58(4):467–48610.1016/j.addr.2006.03.007 ↗
38. Patil GV (2003) Biopolymer albumin for diagnosis and in drug delivery. Drug Dev Res 58(3):219–24710.1002/ddr.10157 ↗
39. Rahbari R, Sheahan T, Modes V, Collier P, Macfarlane C, Badge RM (2009) A novel L1 retrotransposon marker for HeLa cell line identification. Biotechniques 46(4):277–28410.2144/000113089 ↗
40. Ren L–L, Wu Y, Han D, Zhao L-D, Sun Q-M, Guo W–W, Sun J-H, Wu N, Li X-Q, Zhai S-Q, Han D-Y, Young W-Y, Yang S-M (2010) Math1 gene transfer based on the delivery system of quaternized chitosan/Na-carboxymethyl–cyclodextrin nanoparticles. J Nanosci Nanotechnol 10(11):7262–726510.1166/jnn.2010.2822 ↗
41. Rubino OP, Kowalsky R, Swarbrick J (1993) Albumin microspheres as a drug delivery system: relation among turbidity ratio, degree of cross-linking, and drug release. Pharm Res 10(7):1059–106510.1023/A:1018979126326 ↗
42. Shao D, Sun H, Yu M, Lian J, Sawyer S (2012) Enhanced ultraviolet emission from poly(vinyl alcohol) ZnO nanoparticles using a SiO2–Au core/shell structure. Nano Lett 12(11):5840–584410.1021/nl3031955 ↗
43. Singh HD, Wang G, Uludag H, Unsworth LD (2010) Poly-l-lysine-coated albumin nanoparticles: stability, mechanism for increasing in vitro enzymatic resilience, and siRNA release characteristics. Acta Biomater 6(11):4277–428410.1016/j.actbio.2010.06.017 ↗
44. Soto-Cruz O, Saucedo-Castañeda G, Pablos-Hach JL, Gutiérrez-Rojas M, Favela-Torres E (1999) Effect of substrate composition on the mycelial growth of Pleurotus ostreatus. An analysis by mixture and response surface methodologies. Process Biochem 35(1–2):127–13310.1016/S0032-9592(99)00043-6 ↗
45. Utsuno K, Uludag H (2010) Thermodynamics of polyethylenimine-DNA binding and DNA condensation. Biophys J 99(1):201–20710.1016/j.bpj.2010.04.016 ↗
46. Wang G, Siggers K, Zhang S, Jiang H, Xu Z, Zernicke RF, Matyas J, Uludag H (2008) Preparation of BMP-2 containing bovine serum albumin (BSA) nanoparticles stabilized by polymer coating. Pharm Res 25(12):2896–290910.1007/s11095-008-9692-2 ↗
47. Weber C, Coester C, Kreuter J, Langer K (2000a) Desolvation process and surface characterisation of protein nanoparticles. Int J Pharm 194(1):91–10210.1016/S0378-5173(99)00370-1 ↗
48. Weber C, Kreuter J, Langer K (2000b) Desolvation process and surface characteristics of HSA-nanoparticles. Int J Pharm 196(2):197–20010.1016/S0378-5173(99)00420-2 ↗
49. Xu J, Yang X, Wang H, Chen X, Luan C, Xu Z, Lu Z, Roy VAL, Zhang W, Lee C-S (2011) Arrays of ZnO/ZnxCd1–xSe nanocables: band gap engineering and photovoltaic applications. Nano Lett 11(10):4138–414310.1021/nl201934k ↗
50. Xu P, Li W, Zhou H, Pan F, Xing H, Liu H (2012) Investigations of the structural evolution of electrospun nanofibers using atomic force microscopy. RSC Advances 2(29):11104–1111010.1039/c2ra20146a ↗
51. Zhang S, Wang G, Lin X, Chatzinikolaidou M, Jennissen HP, Laub M, Uludag H (2008) Polyethylenimine-coated albumin nanoparticles for BMP-2 delivery. Biotechnol Prog 24(4):945–95610.1002/btpr.12 ↗
52. Zhang S, Kucharski C, Doschak MR, Sebald W, Uludag H (2010) Polyethylenimine-PEG coated albumin nanoparticles for BMP-2 delivery. Biomaterials 31(5):952–96310.1016/j.biomaterials.2009.10.011 ↗